Roushun Kojic Skin Lightening Nutural Skin Care Treament Serum 30ml

Dosage of Hyaluronic Acid is highly specific to the indication and the particular brand-name product being used, as molecular weights and concentrations vary widely.

Osteoarthritis (Intra-articular Injection)

• Standard Regimen: Most traditional HA products (e.g., Hyalgan, Supartz) require a series of 3 to 5 injections, typically administered once weekly (e.g., 20 mg to 25 mg per injection).
• Single-Injection Regimen: High-molecular-weight or cross-linked products (e.g., Synvisc-One, Durolane) are administered as a single 6 mL (approx. 48 mg to 60 mg) dose into the knee joint.
• Duration of Effect: Benefits typically peak at 8 to 12 weeks and can last for up to 6 months.

Dermal Fillers (Aesthetic Use)

• Dosage: The volume injected depends entirely on the area being treated and the degree of volume loss. Typical treatments use 0.5 mL to 2.0 mL per session.
• Frequency: Maintenance treatments are usually required every 6 to 12 months.

Ophthalmic Use

• Surgical: The amount used is determined by the surgeon based on the volume of the anterior chamber, typically 0.2 mL to 1.0 mL.
• Dry Eye: 1-2 drops in the affected eye(s) as needed, usually 3 to 4 times daily.

Hyaluronic Acid is generally not approved for use in pediatric populations. The safety and effectiveness of intra-articular injections or dermal fillers in patients under the age of 18 have not been established. Use in children is restricted to specific ophthalmic surgical needs as determined by a specialist.

Renal Impairment

Because Hyaluronic Acid injections (intra-articular or dermal) act locally and have minimal systemic absorption, no specific dosage adjustments are required for patients with renal impairment. However, systemic clearance of degraded fragments may be theoretically slower in end-stage renal disease.

Hepatic Impairment

No dosage adjustments are established for patients with hepatic impairment. While the liver is the primary site for the clearance of systemic HA, the local nature of most HA therapies makes hepatic toxicity or accumulation unlikely.

Elderly Patients

No specific dosage adjustments are required for the elderly. In fact, the majority of patients receiving HA for osteoarthritis are over the age of 65. Clinical trials have shown that the safety profile in the elderly is comparable to that in younger adults.

• Injections: Intra-articular and dermal injections must be performed by a licensed healthcare professional using strict aseptic (sterile) technique. For joint injections, the site should be cleaned with an antiseptic like betadine or alcohol.
• Topical Use: Apply to clean, slightly damp skin to maximize the humectant (moisture-binding) properties of the HA.
• Storage: Most HA injections should be stored at room temperature (15°C to 30°C or 59°F to 86°F), though some specific brands may require refrigeration. Do not freeze. Protect from light.

If you miss an appointment for a weekly joint injection, contact your healthcare provider immediately to reschedule. The series must be completed to achieve the full therapeutic effect. If a dose is missed by more than a few days, the provider may need to restart the series or adjust the schedule.

Systemic overdose of Hyaluronic Acid is virtually impossible with standard clinical use. However, a "local" overdose (injecting too much into a joint or skin area) can occur.

• Signs of Local Overdose: Severe pain, extreme swelling, localized bruising, and restricted range of motion in the joint. In dermal fillers, overfilling can lead to the "Tyndall effect" (a bluish hue under the skin) or palpable lumps.
• Emergency Measures: For dermal fillers, an enzyme called hyaluronidase can be injected to rapidly dissolve the excess HA. For joint injections, the provider may need to aspirate (drain) the excess fluid from the joint space.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to self-inject without medical guidance.

Side effects of Hyaluronic Acid are most frequently related to the injection procedure itself rather than the substance.

• Injection Site Pain: A sharp or dull ache at the site of the needle entry, which usually subsides within 24 to 48 hours.
• Swelling (Edema): Localized puffiness around the joint or the treated facial area. This is a natural inflammatory response to the needle and the volume of the gel.
• Bruising (Ecchymosis): Small purple or blue marks caused by minor capillary bleeding during the injection.
• Redness (Erythema): Temporary flushing of the skin at the injection site.
• Joint Stiffness: A feeling of fullness or "tightness" in the knee after a viscosupplementation injection.

• Pruritus (Itching): An itchy sensation at the site of injection, which may indicate a mild localized hypersensitivity.
• Headache: Some patients report mild tension-type headaches following treatment.
• Muscle Aches (Myalgia): Generalized muscle soreness or stiffness not limited to the injection site.
• Nausea: Mild gastrointestinal upset has been reported in a small percentage of patients following joint injections.

• Localized Infection: Despite sterile techniques, bacteria can occasionally enter the joint or skin, leading to septic arthritis or cellulitis.
• Granuloma Formation: Small, firm bumps that develop months after a dermal filler injection as the body's immune system reacts to the foreign material.
• Tyndall Effect: A bluish discoloration of the skin caused by HA filler being injected too superficially, scattering light.
• Lymphatic Obstruction: Temporary swelling of nearby lymph nodes.

> Warning: Stop using Hyaluronic Acid products and call your doctor immediately if you experience any of these serious reactions:

• Anaphylaxis: Signs include difficulty breathing, swelling of the face, lips, or tongue, hives, and a rapid heartbeat. This is extremely rare but can occur in patients with allergies to avian (bird) proteins if the HA is derived from rooster combs.
• Septic Arthritis: Severe, escalating pain in the joint, significant warmth, redness, and fever. This is a medical emergency requiring joint drainage and antibiotics.
• Vascular Occlusion (Dermal Fillers): If HA is accidentally injected into a blood vessel, it can block blood flow. Symptoms include immediate, severe pain and blanching (whitening) of the skin, followed by a dusky or mottled appearance. This can lead to skin necrosis (tissue death) or, in very rare cases, blindness if the vessel supplies the eye.
• Severe Allergic Reaction (Hylan G-F 20): Some patients may experience a "pseudo-septic" reaction—a sudden, massive inflammatory response in the joint without infection.

With repeated use of intra-articular Hyaluronic Acid, there are no known systemic long-term side effects. However, repeated injections into the same joint carry a cumulative risk of infection or localized tissue scarring. For dermal fillers, long-term use can occasionally lead to "filler fatigue," where the skin may appear slightly stretched or the filler may migrate to adjacent areas, requiring dissolution with hyaluronidase.

No FDA black box warnings currently exist for Hyaluronic Acid. It is generally considered one of the safest injectable materials available due to its biocompatibility with human tissue.

Report any unusual symptoms, especially those involving vision changes or severe skin discoloration, to your healthcare provider immediately.

Hyaluronic Acid is highly biocompatible, but it is not without risks. Patients must ensure they are receiving treatment from qualified, licensed professionals. Products sourced from unverified online vendors or "at-home" injection kits pose a severe risk of infection, disfigurement, and vascular injury.

There are no FDA black box warnings for Hyaluronic Acid as of 2026.

• Avian Allergy: Many forms of Hyaluronic Acid (such as Hyalgan or Synvisc) are manufactured from rooster combs. Patients with a known hypersensitivity to avian proteins, feathers, or egg products must inform their doctor. Synthetic (bio-fermented) versions are available for these patients.
• Active Infection: HA should never be injected into a joint or skin area that has an active infection or skin disease (e.g., psoriasis, herpes outbreak, or cellulitis). This can spread the infection into deeper tissues.
• Circulatory Disorders: Patients with venous or lymphatic stasis in the leg should be treated with caution when receiving knee injections, as the risk of localized skin complications is higher.
• Bleeding Disorders: While HA itself does not affect clotting, the act of injection can cause significant hematoma (blood collection) in patients with hemophilia or those taking high-dose anticoagulants.
• Vascular Safety: When used as a dermal filler, the provider must have extensive knowledge of facial anatomy to avoid intra-arterial injection, which can cause tissue necrosis or vision loss.

There are no routine laboratory tests (like blood counts or liver panels) required for patients using Hyaluronic Acid. Monitoring is primarily clinical:

• Post-Injection Observation: Patients should be monitored for 15-30 minutes after the first injection for signs of immediate hypersensitivity.
• Joint Assessment: For osteoarthritis, the doctor will assess the range of motion and pain levels at follow-up visits.
• Skin Assessment: For fillers, the patient should monitor for any persistent redness, lumps, or changes in skin color.

Hyaluronic Acid does not cause sedation or cognitive impairment. However, if a joint injection causes significant temporary pain or stiffness, patients should avoid driving until they feel they have full control of the limb. Ophthalmic drops may cause temporary blurred vision immediately after application.

There is no direct chemical interaction between Hyaluronic Acid and alcohol. However, patients receiving dermal fillers are advised to avoid alcohol for 24-48 hours before and after the procedure. Alcohol acts as a vasodilator (widens blood vessels), which can significantly increase the risk of bruising and swelling at the injection site.

Hyaluronic Acid does not require a tapering period. If a patient decides to stop viscosupplementation, the only consequence is the gradual return of original osteoarthritis symptoms as the HA is naturally metabolized. Dermal fillers will slowly dissipate over months, and the skin will return to its baseline appearance.

> Important: Discuss all your medical conditions, especially allergies and circulatory issues, with your healthcare provider before starting Hyaluronic Acid.

• Quaternary Ammonium Salts: Hyaluronic Acid must NEVER come into contact with disinfectants containing quaternary ammonium salts (such as benzalkonium chloride). These chemicals cause Hyaluronic Acid to precipitate (turn into a solid), which can cause severe tissue irritation and render the treatment ineffective. Healthcare providers must ensure the skin is not prepped with these specific agents.

• Anticoagulants (e.g., Warfarin, Rivaroxaban, Apixaban): While there is no pharmacological interaction, the risk of a significant hematoma (internal bruise) at the injection site is greatly increased. Patients should not stop these medications without a doctor's order, but the provider may use a finer needle or apply prolonged pressure.
• Antiplatelet Agents (e.g., Clopidogrel, Aspirin): Similar to anticoagulants, these increase the risk of bruising and swelling after HA injections.

• Topical Retinoids (e.g., Tretinoin): When using topical HA for skincare, retinoids may increase the permeability of the skin. This is often beneficial for hydration but can increase irritation in sensitive individuals.
• Intra-articular Corticosteroids: Doctors often combine HA with a steroid injection. While generally safe, the steroid may slightly alter the degradation rate of the HA, though this is often clinically managed to provide both immediate and long-term pain relief.

• No Significant Interactions: There are no known foods that interfere with the efficacy of Hyaluronic Acid.
• Hydration: Because HA is a humectant, maintaining adequate systemic hydration (drinking plenty of water) may theoretically support the volumizing effects of HA in the skin and joints.

• Vitamin E, Ginkgo Biloba, and Garlic: These supplements have mild blood-thinning properties. Patients are often advised to stop taking them 7 days before an HA injection to minimize the risk of bruising.
• St. John's Wort: No known interaction with HA, but always inform your provider of its use due to its effect on other medications.
• Arnica Montana: Often used as a homeopathic remedy to reduce bruising after HA fillers; there is no known negative interaction.

Hyaluronic Acid does not typically interfere with standard blood or urine laboratory tests. However, it may appear as a "soft tissue mass" on certain high-resolution MRI or CT scans if a large volume of filler was recently injected, which could be misinterpreted by a radiologist unaware of the treatment.

For each major interaction, the primary concern is the physical stability of the HA molecule or the increased risk of procedural complications (bleeding). There are no known CYP450 enzyme interactions because HA is not metabolized by the liver's microsomal system.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect blood clotting.

Hyaluronic Acid must NEVER be used in the following circumstances:

• Known Hypersensitivity: Any patient with a history of anaphylaxis or severe allergy to Hyaluronic Acid or its components.
• Avian Protein Allergy: For products derived from rooster combs (e.g., Synvisc, Hyalgan), patients with a severe allergy to feathers, eggs, or poultry are strictly contraindicated.
• Infection at the Injection Site: Injecting HA into an infected area (cellulitis, abscess) or an infected joint (septic arthritis) can lead to systemic sepsis or permanent joint destruction.
• Skin Disease in the Treatment Area: For dermal fillers, active acne, rashes, or herpes sores in the target area are absolute contraindications until the skin has fully healed.

These conditions require a careful risk-benefit analysis by a physician:

• Autoimmune Disorders: Patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis may have a higher risk of inflammatory reactions to dermal fillers.
• Bleeding Diathesis: Patients with a natural tendency to bleed excessively require specialized technique and post-procedure monitoring.
• Previous Keloid Formation: Patients prone to thick, raised scars (keloids) may have a higher risk of scarring at the injection site.
• Recent Dental Work: For dermal fillers around the mouth, recent dental procedures (within 2 weeks) increase the risk of bacteria entering the bloodstream and colonizing the filler material.

• Gram-Positive Bacterial Proteins: Some HA products are produced via fermentation of Streptococcus bacteria. Patients with a known severe allergy to such bacterial proteins should use avian-derived products instead.
• Lidocaine: Many dermal fillers (e.g., Juvederm XC) contain lidocaine for comfort. Patients allergic to local anesthetics of the amide type must use "non-lidocaine" versions.

> Important: Your healthcare provider will evaluate your complete medical history, including all allergies, before prescribing or administering Hyaluronic Acid.

Hyaluronic Acid is categorized as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and there are no adequate and well-controlled studies in pregnant women.

• Risk Assessment: Because HA is a naturally occurring substance and intra-articular or dermal injections result in minimal systemic exposure, the risk to the fetus is considered low. However, elective aesthetic procedures (fillers) are generally deferred until after pregnancy to avoid any unnecessary risk.
• Clinical Guidance: HA should only be used during pregnancy for medical indications (like joint pain) if the potential benefit justifies the potential risk to the fetus.

It is not known whether Hyaluronic Acid is excreted in human milk. However, due to its very high molecular weight, it is highly unlikely that significant amounts would pass into breast milk or be absorbed by the nursing infant's gastrointestinal tract. Most clinicians consider HA injections compatible with breastfeeding, though elective cosmetic fillers are often postponed as a precaution.

Safety and effectiveness in pediatric patients (under age 18) have not been established. The use of HA in children is rare and typically limited to specialized ophthalmic surgeries. The impact of HA injections on growing epiphyses (growth plates) in children's joints has not been studied.

The majority of clinical data for Hyaluronic Acid in osteoarthritis comes from patients aged 65 and older.

• Efficacy: Studies show that elderly patients respond similarly to younger adults in terms of pain relief.
• Safety: There is no increased risk of adverse events in the geriatric population. However, providers should be mindful of skin fragility in the elderly when performing dermal injections to avoid tearing or extensive bruising.
• Pharmacokinetics: Age-related declines in renal or hepatic function do not significantly impact the local clearance of HA.

No dosage adjustments are required for patients with kidney disease. The local metabolism of HA by hyaluronidase enzymes means the kidneys do not play a primary role in the initial breakdown of the drug. Even in patients on dialysis, HA injections are considered safe.

No dosage adjustments are required for patients with liver disease. While the liver is involved in clearing HA fragments from the blood, the systemic concentrations following local injection are too low to cause concern in patients with cirrhosis or other hepatic conditions.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are pregnant or nursing before receiving an injection.

Hyaluronic Acid functions as a biological lubricant and structural stabilizer. At the molecular level, HA binds to the CD44 receptor and the Receptor for Hyaluronan-Mediated Motility (RHAMM).

• Viscosupplementation: In the joint, HA increases the viscosity of the synovial fluid, which follows the principles of non-Newtonian fluid dynamics. At low shear rates (slow movement), it provides high viscosity for lubrication. At high shear rates (impact/running), it becomes elastic to absorb shock.
• Anti-inflammatory: HA can inhibit the release of inflammatory mediators like prostaglandins and cytokines (IL-1β) in the joint space, potentially slowing the degradation of remaining cartilage.
• Hydroscopic Volumization: In the skin, the carboxyl groups on the HA molecule create a negative charge that attracts water, creating a hydrated gel matrix that supports collagen and elastin fibers.

• Onset of Action: For dry eyes, relief is immediate. For dermal fillers, the volumizing effect is immediate. For osteoarthritis, the onset of pain relief is slow, usually requiring 3 to 5 weeks to become noticeable.
• Duration of Effect: Joint injections typically provide relief for 6 months. Dermal fillers last 6 to 18 months. Topical HA lasts only as long as the product remains on the skin (hours).
• Tolerance: There is no known pharmacological tolerance to HA; however, the underlying disease (osteoarthritis) may progress, making subsequent treatments seem less effective.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local Injection) |

| Protein Binding | Minimal |

| Half-life (Plasma) | 2–5 minutes |

| Half-life (Joint) | 20 hours to 8 days (depending on cross-linking) |

| Tmax | 1–2 hours (local tissue concentration) |

| Metabolism | Local hyaluronidase enzymes |

| Excretion | Renal (small fragments), Lungs (as CO2) |

• Molecular Formula: (C14H21NO11)n
• Molecular Weight: 500,000 to 6,000,000 Daltons (varies by product)
• Solubility: Highly soluble in water; forms a viscoelastic gel.
• Structure: A linear polysaccharide consisting of alternating D-glucuronic acid and N-acetyl-D-glucosamine units linked by β(1→4) and β(1→3) glycosidic bonds.

Hyaluronic Acid is a Glycosaminoglycan and a Viscosupplement. While it is sometimes grouped with CNS stimulants or vitamins in specific regulatory databases (as noted in the EPC classes), these do not reflect its clinical therapeutic use. It is most closely related to other joint lubricants like Chondroitin Sulfate.